ICAAC 45th

Title Content type
Antifungal Activity of BAL4815, a Novel Azole Against Dermatophytes and Emerging Non-Dermatophyte Fungi Including Zygomycetes (click for details)
In vitro activity of the new azole BAL4815 against clinical dermatophyte isolates (click for details)
In Vitro Activity of the New Azole BAL4815 against Clinical Candida Isolates Comprising Resistant C. albicans and Less Susceptible Candida spp (click for details)
Efficacy, Safety, and Tolerability of three Different Dosing Regimens of BAL8557 Vs. Fluconazole in a Double-Blind, Randomized, Multicenter Trial for the Treatment of Esophageal Candidiasis in Immunocompromised Adults (click for details)
In vivo Efficacy of the triazole BAL8557 (BAL) Compared to Voriconazole (VOR), Itraconazole (ITC) and Caspofungin (CAS) By a New qPCR and Quantitative Culture in a Neutropenic Murine Model of Aspergillus flavus (click for details)
Dose Response Curves and Dose Fractionation Studies with BAL8557 in a Murine Model of Disseminated Candidiasis (click for details)
Nanosuspension Formulation of Itraconazole Increases Survival Relative to Solution Formulation in Immunocompromised Rat Model of Itraconazole-Resistant C. Albicans Infection (click for details)
Activity of New and Investigational Antifungal Agents against Recent Clinical Isolates of Filamentous Fungi (click for details)
Effects of Voriconazole in Combination with Caspofungin and GM-CSF on Intracellular Killing of Candida glabrata in Human Monocyte-Derived Macrophages (click for details)
Efficacy of Liposomal Amphotericin B (L-Ab) Combined with Caspofungin (Cs) in the Treatment of Experimental Pulmonary Aspergillosis (EPA) (click for details)


Subscribe to ICAAC 45th